Estimates and Trends of the Global Burden of NASH-Related Liver Cancer Attributable to High Fasting Plasma Glucose in 1990–2019: Analysis of Data From the 2019 Global Burden of Disease Study

Aggrego Pulse - 3/23/23

Can Lymph Nodes Boost the Success of Cancer Immunotherapy?

Response High for Bispecific Antibody Talquetamab in Multiple Myeloma

Depression Tied to Inflammation and Survival in Lung Cancer

Gut Microbiome May Influence How Patients With Non-Hodgkin Lymphoma Respond to CAR T-Cell Therapy

Exploring the Acceptability of the ‘Smart Cane’ to Support Mobility in Older Cancer Survivors and Older Adults

Adding Bortezomib to DRC Does Not Improve PFS in Waldenström Macroglobulinemia

Estimates and Trends of the Global Burden of NASH-Related Liver Cancer Attributable to High Fasting Plasma Glucose in 1990–2019: Analysis of Data From the 2019 Global Burden of Disease Study

header-info

01/20/2023

In the present study, we aimed to assess the burden of NASH-related liver cancer attributable to hyperglycemia, using estimates derived from epidemiological studies. We also aimed to evaluate the relative roles of the sociodemographic index (SDI) and age in the observed trend of hyperglycemia-induced NASH-related liver cancer burden.